The "J curve" problem revisited: Old and new findings

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 290-295

  Grassi, Guido ^a   Quarti Trevano, Fosca ^a   Dell'Oro, Raffaella ^a   Mancia, Giuseppe ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Antihypertensive treatment; Blood pressure goals; Cardiovascular protection; Coronary artery disease; Guidelines; J curve

Indexed keywords

AMLODIPINE; ENALAPRIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; J CURVE PHENOMENON; MORBIDITY; MORTALITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESSURE VOLUME CURVE; RENAL PROTECTION; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CORONARY ARTERY DISEASE; HUMANS; HYPERTENSION; ITALY; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; WORLD HEALTH;

EID: 77956269095     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0121-7     Document Type: Review

References (44)

1. •• Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187. This paper represents the official guidelines for the diagnosis and management of high blood pressure jointly issued by the ESH and ESC.
2. A Zanchetti A Amery G Berglund, et al. 1989 How much should blood pressure be lowered? The problem of the J-shaped curve J Hypertens Suppl 7 S338 S348 1:STN:280:DyaK3c3hvVCgtA%3D%3D 2632738
3. •• Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158. The ESH decided in 2009 to update the recommendations on hypertension management, based on the results of major clinical trials published in the period 2007 to 2009.
4. R Collins S MacMahon 1994 Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease Br Med Bull 50 272 298 1:STN:280:DyaK2c3msFSksA%3D%3D 8205459
5. H Arima J Chalmers M Woodward, et al. 2006 Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial J Hypertens 24 1201 1208 10.1097/01.hjh.0000226212.34055.86 1:CAS:528:DC%2BD28Xktlartbg%3D 16685221
6. GL Bakris M Williams L Dworkin, et al. 2000 Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 646 661 1:STN:280:DC%2BD3cvjsFSqsw%3D%3D 10977801
7. UK Prospective Diabetes Study Group 1998 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 703 713
8. T Berl LG Hunsicker JB Lewis, et al. 2003 Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 542 549 1:CAS:528:DC%2BD3sXjtVejt7Y%3D 12667024
9. RO Estacio BW Jeffers N Gifford RW Schrier 2000 Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 B54 B64 10860192
10. Patel A; MacMahon S, Chalmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
11. CJ Pepine EM Handberg RM Cooper-DeHoff, et al. 2003 A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2805 2816 10.1001/jama.290.21. 2805 1:CAS:528:DC%2BD3sXps1Crurk%3D 14657064
12. KM Fox 2003 EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 782 788 10.1016/S0140-6736(03) 14974-4 1:STN:280:DC%2BD3svjvVGhtw%3D%3D 13678872
13. SE Nissen EM Tuzcu P Libby, et al. 2004 Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study-a randomized controlled trial JAMA 292 2217 2225 10.1001/jama.292.18.2217 1:CAS:528:DC%2BD2cXpslyqt78%3D 15536108
14. S Yusuf P Sleight J Pogue, et al. 2000 Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 145 153 10.1056/NEJM200001203420301 1:STN:280:DC%2BD3c%2Fpt1emug%3D%3D 10639539
15. PROGRESS Collaborative Study Group 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack Lancet 358 1033 1041 10.1016/S0140-6736(01)06178-5
16. PATS Collaborating Group 1995 Post-stroke antihypertensive treatment study. A preliminary result Chin Med J (Engl) 108 710 717
17. A Zanchetti 1992 To what level should blood pressure be brought by antihypertensive treatment? High Blood Press 1 197 200
18. IM Stewart 1979 Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension Lancet 1 8121 861 865 10.1016/S0140-6736(79)91274-1 1:STN:280:DyaE1M7lsFOqsQ%3D%3D 86103
19. JM Cruickshank JM Thorp FJ Zacharias 1987 Benefits and potential harm of lowering high blood pressure Lancet 1 8533 581 584 10.1016/S0140-6736(87)90231-5 1:STN:280:DyaL2s7ktleqsg%3D%3D 2881129
20. MH Alderman WL Ooi S Madhavan H Cohen 1989 Treatment-induced blood pressure reduction and the risk of myocardial infarction JAMA 262 920 924 10.1001/jama.262.7.920 1:STN:280:DyaL1MzivFWhuw%3D%3D 2754792
21. O Samuelsson L Wilhelmsen OK Andersson, et al. 1987 Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden JAMA 258 1768 1776 10.1001/jama.258.13.1768 1:STN:280:DyaL2szht1Wisg%3D%3D 3625987
22. S Yusuf HC Diener RL Sacco, et al. 2008 Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 1225 1237 10.1056/ NEJMoa0804593 1:CAS:528:DC%2BD1cXhtFGjur3O 18753639
23. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators 2008 Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 1174 1183 10.1016/S0140-6736(08)61242-8
24. S Julius SE Kjeldsen M Weber, et al. 2004 Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022 2031 10.1016/S0140-6736(04)16451-9 1:CAS:528:DC%2BD2cXltVCitro%3D 15207952
25. FH Messerli G Mancia CR Conti, et al. 2006 Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144 884 893 16785477
26. • Sleight P, Redon J, Verdecchia P, et al.: Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009, 27:1360-1369. This paper provides a new evaluation of the ONTARGET Study, analyzing the blood pressure goal data in relation to cardiovascular events in high-risk individuals.
27. S Bangalore FH Messerli C Wun, et al. 2009 J-Curve revisited: an analysis of the Treating to New Targets (TNT) Trial [poster 1039-70] J Am Coll Cardiol 53 A217
28. S Lewington R Clarke N Qizilbash, et al. 2002 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903 1913 10.1016/S0140-6736(02)11911-8 12493255
29. •• Zanchetti A, Mancia G, Black HR, et al.: Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009, 27:673-679. This editorial addresses some of the current clinical problems in hypertension management, with particular emphasis on the position of beta blockers.
30. F Boutitie F Gueyffier S Pocock, et al. 2002 J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data Ann Intern Med 136 438 448 11900496
31. •• Zanchetti A, Grassi G, Mancia G: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009, 27:923-934. This is an updated analysis of the results of major clinical trials aimed at defining blood pressure levels at which antihypertensive treatment should start and blood pressure goals.
32. G Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 2003 21 1011 1053
33. L Liu Y Zhang G Liu, et al. 2005 The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients J Hypertens 23 2157 2172 10.1097/01.hjh.0000194120.42722.ac 1:CAS:528:DC%2BD2MXhtFOhsLbN 16269957
34. Hypertension, Detection and Follow-up Program Cooperative Group 1982 Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure JAMA 247 633 638 10.1001/jama.247.5.633
35. Medical Research Council Working Party 1985 MRC trial of treatment of mild hypertension: principal results Br Med J 291 97 104 10.1136/bmj.291.6488.97
36. A Helgeland 1980 Treatment of mild hypertension: a five year controlled drug trial. The Oslo study Am J Med 69 725 732 10.1016/0002-9343(80)90438-6 1:STN:280:DyaL3M%2FlvFKiug%3D%3D 7001898
37. L Hansson A Zanchetti SG Carruthers, et al. 1998 Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1755 1762 10.1016/S0140-6736(98)04311-6 1:CAS:528:DyaK1cXksV2qtrY%3D 9635947
38. JATOS Study Group 2008 Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS) Hypertens Res 31 2115 2127 10.1291/hypres.31.2115
39. RW Schrier RO Estacio A Esler P Mehler 2002 Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke Kidney Int 61 1086 1097 10.1046/j.1523-1755.2002.00213.x 11849464
40. The Heart Outcomes Prevention Evaluation (HOPE) Study investigators 2000 Effects of ramipril on cardiovascular and microvascular outcomes in MICROHOPE substudy Lancet 355 253 259 10.1016/S0140-6736(99)12323-7
41. B Pitt RP Byington CD Furberg, et al. 2000 Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events Circulation 102 1503 1510 1:CAS:528:DC%2BD3cXntFKnsLc%3D 11004140
42. PA Poole-Wilson J Lubsen BA Kirwan, et al. 2004 Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial Lancet 364 849 857 10.1016/S0140-6736(04)16980-8 1:CAS:528:DC%2BD2cXntlaqsLw%3D 15351192
43. The PEACE Trial Investigators 2004 Angiotensin-converting-enzyme inhibition in stable coronary disease N Engl J Med 351 2058 2068 10.1056/NEJMoa042739
44. J Schrader S Luders A Kulschewski, et al. 2003 The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors Stroke 34 1699 1703 10.1161/01.STR.0000075777.18006.89 12817109